HCV NS5A News
Most Popular HCV NS5A Story
Presidio rounds up $27M for clinical studies
With help from new investor New Leaf Venture Partners, Presidio Pharmaceuticals has closed a $27 million financing, bringing the company's total amount of funds raised to $54.5 million. Existing Read more...
Latest Headlines
- July 10, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
